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Summary
Objective: Quantitation and analyses of the fine structure of glycosaminoglycans are increasingly important for understanding many
biological processes, including those most critical for understanding skeletal biology. We have developed a novel procedure, fluorophore-
assisted carbohydrate electrophoresis (FACE), for determination of glycosaminoglycan fine structure and estimation of chain length.
Design: FACE utilizes enzymes that cleave glycosaminoglycans to create products, usually disaccharides, characteristic of the enzyme
specificity. Each cleavage exposes a new reducing terminus that is fluorotagged by reductive amination with 2-aminoacridone. The tagged
products are then displayed by electrophoresis, identified by their characteristic migration and chemistry, and quantitated by their molar
fluorescence.
Results: Each class of glycosaminoglycan and the enzymes specific for each class are discussed. Specific application of the FACE
technology is shown for analysis of the glycosaminoglycans on aggrecan isolated from knee cartilage of 5- and 68-year-old patients, and
assessment of hyaluronan oligosaccharides.
Conclusions: The FACE technology is a powerful tool for analysis of all four classes of glycosaminoglycans obtained from a wide variety of
biologic sources. While the FACE protocols are relative simple, they provide a wealth of information including quantitation in the pmole range,
determination of fine structure, and estimation of chain length. © 2001 OsteoArthritis Research Society International
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There are four general classes of glycosaminoglycans: (1)
hyaluronan; (2) chondroitin sulfate and dermatan sulfate;
(3) keratan sulfate; and (4) heparin and heparan sulfate.
With the exception of hyaluronan, glycosaminoglycans are
synthesized covalently bound to core proteins forming the
class of macromolecules called proteoglycans. All cells
synthesize one or more glycosaminoglycans, and the
parent proteoglycans are found inside cells, on their sur-
faces and in extracellular matrices1–3.
Glycosaminoglycans are synthesized as polymers of
repeating disaccharides with an N-acetylhexosamine as
one of the sugars. The alternating sugar is glucuronic acid
with the exception of keratan sulfate which contains galac-
tose instead. The synthesized polymer for hyaluronan is
not modified further, whereas the other three classes are
modified by: (1) the addition of O-sulfates on various
hydroxyls (all three classes); (2) 5-epimerization of some
glucuronic acid residues to form iduronic acid residues
(dermatan sulfate, heparin/heparan sulfate); and (3)
removal of acetyl residues from some hexosamines and
replacing them with N-sulfates (heparin/heparan sulfate).
These modifications introduce fine structures within theS16chains that often have major roles in a wide variety of
biological processes.Enzymes that degrade glycosaminoglycans
The reducing ends of glycosaminoglycan chains on
proteoglycans are covalently attached to their core proteins
and hence have no free reducing groups. It is uncertain
whether or not a hyaluronan chain is substituted on its
reducing end. However, the length of the polymer, often
with 10 000 or more repeating disaccharides, is such that a
single free reducing group would not be detectable by the
procedures described below. There are two classes of
enzymes that selectively degrade glycosaminoglycans:
hydrolases, which add water across the bond being
cleaved, and lyases (eliminases), which in effect remove
water between the 4-5 carbons of hexuronic acid residues
with hydrolysis of the glycoside bond from the 4-carbon
(Fig. 1). This leaves a ∆4,5 unsaturated bond on the
hexuronic acid. Each cleavage, whichever class of
enzyme, creates a free reducing group that can be fluoro-
tagged for subsequent identification. Characteristics of
some of the enzymes which degrade each class of gly-
cosaminoglycan and which are commercially available are
described below.HYALURONAN
Testicular hyaluronidase, an endo hexosaminidase,
degrades both hyaluronan and chondroitin sulfate (Fig. 1).Address correspondence to: Dr Vincent C. Hascall, Biomedical
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produces predominantly hexa- and tetrasaccharides with
non-reducing terminal glucuronic acid residues and reduc-
ing terminal N-acetylhexosamines4–6. The hyaluronidase
from Streptomyces, an endoeliminase, is specific for
hyaluronan; and, as for all eliminases, the cleavage is
irreversible. The limit digestion contains hexa- and tetra-
saccharides, in this case with non-reducing terminal
∆-hexuronic acid residues and reducing terminal
N-acetylglucosamines7. The hyaluronidase from Strepto-
coccus dyslatea is an eliminase that will also cleave
un-sulfated regions in chondroitin sulfate chains. This
enzyme is processive in that it has preference for cleaving
disaccharides from non-reducing termini over endo activity.
The limit digest contains β-disaccharides with non-reducing
terminal β-hexuronic acid residues and reducing terminal
N-acetylhexosamines.CHONDROITIN SULFATE AND DERMATAN SULFATE
The chondroitinases (ABC, protease free ABC, AC and
B) are processive eliminases (Fig. 1) with specificites for
chondroitin sulfate (ABC and AC) and dermatan sulfate
(ABC and B)7,8. Chondroitinase ABC also cleaves hya-
luronan, but less effectively. The limit products are
∆-disaccharides from the cleaved regions of the chains,
except in the case of protease free chondroitinase ABC
which exhibits more restricted specificity, e.g. generates
mixtures of β-di- and β-tetrasaccharides from the chain
interior, and trisaccharides from the non-reducing termini of
chains ending with sulfated GalNAc residues9.KERATAN SULFATE
Keratan sulfate chains are composed of β1,3-Gal-β1,
4-GlcNAc repeats, that are either un-, mono-(Gal-β1,
4-GlcNAc6S) or disulfated (gal6S-β1,4-GlcNAc6S). They
can be depolymerized by a number of microbial
endo-hydrolases10–16, several of which are commercially
available. For example, enzymes from E. freundii(endo-β-galactosidase) or Pseudomonas sp. (keratanase)
hydrolyze internal β1,4-Gal linkages in regions of the gly-
cosaminoglycan that are enriched in monosulfated disac-
charide repeats, thereby releasing the disaccharide
GlcNAc6S-β1,3-Gal. The E. freundii enzyme can addition-
ally depolymerize unsulfated regions yielding GlcNAc-β1,
3-Gal since its activity is not influenced by the sulfation of
the participating glcNAc residue15. Extensive depoly-
merization of keratan sulfate into disaccharides has
been achieved by keratanase II, an endo-N-
acetylglucosaminidase purified from Bacillus sp.16. This
enzyme catalyzes cleavage of β1,3 linkages involving sul-
fated GlcNAc residues and releases the disaccharides,
Gal-β1,4-GlcNAc6S and Gal6S-β1,4-GlcNAc6S.HEPARIN AND HEPARAN SULFATE
Heparan sulfate consists of block structures along
the chain with regions of little or no modification inter-
spersed between highly sulfated and modified regions,
while heparin contains mostly the highly sulfated and
modified regions. Heparanases are mammalian endo-
glucuronidases (hydrolases) that degrade chains to shorter
oligosaccharides with reducing terminal glucuronic acid
residues and non-reducing terminal sulfated glucosamine
residues17–19. Class I heparanases yield products with
highly sulfated domains at the non-reducing ends, while
class II heparanases yield products with such residues
at the reducing end18. The heparitinases, I, II and III,
are eliminases with different specificities of cleavage
depending upon the fine structure at the cleavage site20,21.
Heparitinase I requires an unsulfated or monosulfated
glucosamine (either N-sulfated or N-acetylated and
6-sulfated) in glycosidic linkage with unsubstituted glu-
curonic acid at the cleavage site. Heparitinase II cleaves
bonds in which the glucosamine can be unsulfated or
monosulfated as for heparitinase I adjacent to either glu-
curonic acid or iduronic acid with or without 2-sulfate.
Heparitinase III cleaves between glucosamine with any
degree of substitution adjacent to 2-sulfated iduronic acid.
Thus, each heparitinase can yield a different pattern of
products, while their combined use yields β-disaccharides.Mercuric ion cleavage of â-hexuronic acid
residues
The unsaturated, non-reducing terminal β-hexuronic
acid residues generated by either the chondroitinases or
the heparitinases are susceptible to treatment with mer-
curic ion under mild conditions, while non-reducing terminal
unmodified hexuronic acid residues are not (Fig. 2). The
reaction quantitatively removes the β-hexuronic acid
residue while leaving the rest of the oligosaccharide (or
monosaccharide in the case of β-disaccharides) intact22.Fluorotagging free reducing groups with
2-aminoacridone (AMAC)
The free reducing groups that are exposed by enzyme
cleavage, or by enzyme cleavage followed by mercuric ion
treatment, can be derivatized with 2-aminoacridone by
reductive amination in the presence of cyanoborohydride
(Fig. 3)6,23,24. Initial studies utilized 2-aminopyridine and
defined conditions that achieved quantitative derivatizationFig. 1. Scheme showing the structure of an octasaccharide that
could be derived from chondroitin sulfate. Digestion with testicular
hyaluronidase, a hydrolase with specificity for both hyaluronan
and chondroitin sulfate, would produce two tetrasaccharides with
non-reducing glucuronic acid residues (reaction 1). Subsequent
digestion of these tetrasaccharides with chondroitinase ABC, an
eliminase, would produce two disaccharides with a non-reducing
glucuronic acid residue and two disaccharides with a non-reducing
∆-hexuronic acid residue (reaction 2). The asterices indicate free
reducing aldehydes available for fluorotagging. R: location, which
may be occupied by either a sulfate or a hydroxyl group.
S18 A. Calabro et al.: Fluorophore-assisted carbohydrate electrophoresis of glycosaminoglycanswithout desulfation25,26. The fluorotagging introduces a
highly fluorescent label that provides an identical signal for
every free reducing group.Separation of fluorotagged standards by
electrophoresis
The fluorotagged products can be separated on poly-
acrylamide gels (Glyko monosaccharide gels) and indi-
vidual bands scanned for fluorescence6,27. An example of
the resolution of the known β-disaccharides that would be
found in a standard digestion protocol using a combination
of streptococcal hyaluronidase and chondroitinase ABC for
analysis of chondroitin/dermatan sulfate and hyaluronan isshown in Fig. 4A (lanes 1, 3, 5). Figure 4A (lanes 2, 4,
6) shows the locations of the products that would be
produced when the respective β-disaccharides are
treated with mecuric ion before fluorotagging, i.e. the
N-acetylhexosamines with or without sulfates, which wereFig. 2. Scheme showing the sensitivity of the chondroitinase ABC
digestion products (reaction 2, Fig. 1) to mercuric ion treatment.
The disaccharide with a non-reducing glucuronic acid residue
is stable to mercuric ion treatment while the non-reducing
∆-hexuronic acid residue of the second disaccharide is removed by
the mercuric ion treatment freeing the corresponding hexosamine.
In the absence of 2-sulfation on the hexuronic acid no fluorotagged
product is recovered from the ∆-hexuronic acid residue, while in
the presence of 2-sulfation three unknown flurotagged products
characteristic of 2-sulfation are observed (X1, X2 and X3, see Fig.
4A). The asterices indicate free reducing aldehydes available for
fluorotagging. The Rs indicate locations, which may be occupied
with either a sulfate or a proton group.Closed
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Fig. 3. Reducing sugars in solution are in equilibrium (reaction A)
between a six-member closed pyranose ring conformation and an
open conformation containing a free reducing aldehyde (shaded
box). The amine group (dashed circle) of 2-aminoacridone (AMAC)
reacts with the free reducing aldehyde to form a Schiff base
(reaction B) that is stabilized by reduction with cyanoborohydride
(reaction C). The final AMAC-tagged saccharide yields a fluor-
escent signal dependent solely on the fluorotag, not the chemistry
of the saccharide. The Rs indicate locations, which may be
occupied with either a sulfate or a proton group.Fig. 4. Panel A: ∆-Disaccharide standards from hyaluronan and
chondroitin/dermatan sulfate analysed by fluorophore-assisted
carbohydrate electrophoresis (FACE) without (lanes 1, 3, 5) or with
(lanes 2, 4, 6) prior mercuric ion treatment followed by derivatiz-
ation with 2-aminoacridone (AMAC). Arrows indicate the major
product(s) from the mercuric ion treatment of each ∆-disaccharide.
AMAC-derivatized ∆-disaccharides and their mercuric ion treat-
ment products are from different standard preparations containing
several saccharide concentrations. Note the presence of the X1,
X2 and X3 bands whenever 2-sulfation is present on the
∆-hexuronic acid residue. Panel B: Quantitation of AMAC-
derivatized hyaluronan and chondroitin sulfate ∆-disaccharides
after separation by FACE. Mixtures containing from 6.25 to
100 pmoles each of the indicated AMAC derivatives were separ-
ated by FACE. The gel (inset) was then imaged using a Quantix
cooled-CCD camera, and the images analysed using a Gel-Pro
Analyzer= program6,27. The relative fluorescence for each band is
plotted vs pmoles of ∆-disaccharides as determined by hexuronic
acid analysis (r=0.997, P=0.00022).
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β-hexuronic acid gives no identifiable fluorotagged product
after mercuric ion treatment, the 2-sulfated β-hexuronic
acid does (band X1). The presence of this band, then, is
diagnostic of 2-sulfated hexuronic acid in the original
chondroitin/dermatan sulfate chain. The graph in Fig. 4B
shows the fluorescent response for increasing concen-
trations of four of the β-disaccharides, and shows that: (1)
the molar fluorescence is the same for each; and (2) the
level of detection extends down to the pmol range for the
β-disaccharides.
A similar strategy can be used for heparin/heparan
sulfate. An example of the resolution of several standard
fluorotagged β-disaccharides derived from enzyme diges-
tion of heparin/heparan sulfate is shown in Fig. 5 (lanes −)
as well as fluorotagged products after mercuric ion treat-
ment (lanes +). In this case a Glyko oligosaccharide gel
was used, which gives better resolution for the more highly
sulfated species [Wang, A., unpublished observations].
Again, band X1 is characteristic of β-disaccharides with
2-sulfated β-hexuronic acid.
The enzymes that cleave keratan sulfate are hydrolases
and do not generate unsaturated sugars at the non-
reducing ends of the digestion products. Thus, the products
are not altered by mercuric ion treatment. An example of
the use of these enzymes followed by fluorotagging for
analysis of keratan sulfate on aggrecan is given below.Applications
ANALYSES OF CHONDROITIN SULFATE AND KERATAN SULFATE ON
AGGRECAN
Aggrecan purified from human knee cartilages of a 5-
and a 68-year-old donor were analyzed for chondroitin
sulfate by digesting 2 µg (as glycosaminoglycan deter-
mined by dimethylmethylene blue binding assay) for 4 h
with 2 milli-units of chondroitinase ABC or for keratansulfate by digesting 20 µg consecutively with 2 milli-units of
keratanase II (Bacillus sp.) (4 h) and 2 milli-units of endo-
beta-galactosidase (E. freundii) (18 h). Products from both
digests were fluorotagged before separation and quantita-
tion by FACE (Fig. 6 and Table 1). The FACE analyses
readily display the distinct glycosaminoglycan compositions
of the two aggrecan populations. Aggrecan from young
cartilage contains predominantly chondroitin sulfate (∼92%Fig. 5. Disaccharide standards from heparin/heparan sulfate analyzed by fluorophore-assisted carbohydrate electrophoresis (FACE) without
(−) or with (+) prior mercuric ion treatment followed by derivatization with 2-aminoacridone (AMAC). Arrows indicate the products from the
mercuric ion treatment of each ∆-disaccharide. U: hexuronic acid; G: glucosamine.5 years 68 years
CS KS CS KS
∆di0S
∆di6S
∆di4S
gal-glcNAc(6S)-
gal(6S)-glcNAc(6S)-
NeuA-gal-glcNAc(6S)-
NeuA-gal(6S)-glcNAc(6S)-
CS
KS
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glcNAc-gal-
DiS
MonoS
UnS
gal-(fuc)glcNAc(6S)-
gal-glcNAc(6S)-gal-glcNAc(6S)-
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Fig. 6. Aggrecan samples from human knee cartilages of a 5- and
a 68-year-old donor [see Ref. 26 for sample preparation details]
were digested with chondroitinase ABC or keratanase II plus
endo-beta-galactosidase. The products were fluorotagged and
analysed by FACE. The gel image shows the separation of
chondroitin lyase products from 200 ng of aggrecan (lanes
denoted CS) and keratan sulfate hydrolase products from 2 µg of
aggrecan (lanes denoted KS). The migration positions of the
chondroitin lyase products (∆-Di0S, ∆-Di4S and ∆-Di6S) are indi-
cated in the left hand margins. The migration positions of the
identified keratan sulfate hydrolase products, as well as two
unidentified minor products (denoted **) that are most likely
hexasaccharide intermediates from keratanase II digests, are
shown in the right hand margins. The three sets of digestion
products used for calculation of the keratan sulfate disaccharide
compositions [0S=glcNAc-gal; MS=gal-glcNAc(6S); DiS=gal(6S)-
glcNAc(6S), see Table I] are also given.
S20 A. Calabro et al.: Fluorophore-assisted carbohydrate electrophoresis of glycosaminoglycansof total glycosaminoglycan), while aggrecan from adult
cartilage contains more keratan sulfate (∼32% of the total
glycosaminoglycan). Previously reported differences in sul-
fation of both the glycosaminoglycans are also readily
visualized. Aggrecan chondroitin sulfate from the young
donor is composed of 4 and 6-sulfated disaccharides,
whereas chondroitin sulfate from the adult donor is almost
exclusively of 6-sulfated disaccharides. Keratan sulfate
from both young and adult cartilages is extensively sulfated
at the C6 position of GlcNAc residues. However, in the
adult, an increase in the C6-sulfation of Gal residues and in
the fucosylation of GlcNAc6S residues is seen.NON-REDUCING TERMINI
Previous work used fluorotagging with 2-aminopyridine
and anion exchange on PA1 columns to resolve chondroi-
tinase digestion products of purified human aggrecan
samples from knee cartilage of individuals differing in
age26. The fluorotagged non-reducing termini were ident-
ified and quantitated. This allowed the number average
molecular weights of the chondroitin sulfate chains to be
estimated; i.e. the total mass of digestion products divided
by the number of moles of non-reducing termini. The
results also showed that most chains, ∼85%, terminated
with N-acetylgalactosamine, either 4-sulfated or 4,6 disul-
fated. The latter was only found on aggrecan isolated from
adult individuals, i.e. after reaching skeletal maturity. Simi-
lar analyses of aggrecan from osteoarthritic cartilage
revealed non-reducing termini and internal sulfation
patterns more characteristic of normal cartilage from
individuals immediately before skeletal maturity2,28.
The FACE procedure in combination with selective sul-
fatases and mercuric ion treatment can also resolve and
quantitate the low abundant non-reducing termini6,27. The
analysis in this case requires less time and experimental
manipulation. With the exception of the mercuric ion step,
in which a cation exchange step is used to remove the
mercuric ion, all of the steps are done in the same reaction
tube. Further, the enzymes and reagents do not enter the
gel and hence are not removed prior to analysis. In
the previous procedure, the unsulfated ∆-disaccharide is
lost during the step required to remove the fluorotagging
reagent, and quantitation of the non-reducing terminal
6-sulfated N-acetylgalactosamine was obscured by a minor
side-reaction involving desulfation of the 6-sulfated
β-disaccharide25.QUANTITATION OF HYALURONAN
The β-disaccharide derived from digestion of hyaluronan
by streptococcal hyaluronidase or chondroitinase ABC is
not sulfated and therefore was not recovered in the pre-
vious method25. Thus, the FACE procedure provides an
ideal method for analysis of this glycosaminoglycan. The
advantages include: (1) sensitivity (in the ng range); (2)
rapidity (typically within 1 day); and (3) multiple samples
per analysis (typically 6–8 per gel).
Figure 7 shows an example of the application of FACE
for analyses of purified and partially purified hyaluronan
oligosaccharides prepared by molecular sieve chromatog-
raphy of a testicular hyaluronidase digest (kindly provided
by Dr Markku Tammi, University of Kuopio). The white
arrowheads identify the band originally indicated for each
sample. While the smaller oligosaccharides, such as HA12(6 disaccharide repeats), contain a single dominant
hyaluronan band, the larger oligosaccharides containFig. 7. FACE analyses of 2-aminoacridone (AMAC) derivatized
testicular hyaluronidase products from hyaluronan (HA) recovered
by molecular sieve chromatography. Column fractions correspond-
ing to specific HA oligomer sizes were collected, AMAC-
derivatized, and separated by fluorophore-assisted carbohydrate
electrophoresis (FACE) to confirm size distribution and purity. The
size for each preparation (HA12, HA14, HA16, HA20, HA24 and
HA26) as originally determined by molecular sieve chromatography
is indicated at the bottom of each lane with the band corresponding
to that size indicated by a white arrowhead. The relative positions
of saturated hyaluronan oligomer standards containing one (HA2),
two (HA4), three (HA6), four (HA8), five (HA10) and nineteen (HA38)
disaccharides are indicated by arrows. The black arrowheads
indicate contaminating chondroitin sulfate oligosaccharides.
382
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6
10
8
12 14 16 20 24 26Table I
Calculated from FACE gel
Glycosaminoglycan composition
(mg/mg total S-GAG)
Disaccharide composition
CS KS CS* KS†
0S 4S 6S 0S MS MS(fuc)‡ DS
5 years 0.89 (92%) 0.08 (8%) 8 40 52 4 52 nd¶ 44
68 years 0.52 (68%) 0.26 (32%) 2 4 94 nd¶ 40 12 48
CS: Chondroitin sulfate.
KS: Keratan sulfate.
*Percent of total ∆-disaccharides (0S+4S+6S).
†Percent of total disaccharides (0S+MonoS+DiS).
‡Monosulfated and fucosylated disaccharide.
¶Not detected.
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nantly higher than the originally indicated component. For
example, the HA24 sample shows bands extending up to at
least HA38, reflecting both the resolution of the FACE
method and the difficulty in purifying the higher oligosac-
charides by molecular sieve chromatography. While not
shown, the arrows at the side indicate the positions where
oligosaccharides smaller than HA12 would run. Thus, the
oligosaccharides exhibit a ladder based on molecular size
until HA6, which migrates nearly the same as HA8, while
HA4 and HA2 migrate to anomalous positions higher in the
ladder. Additional bands, indicated by the black arrow-
heads, are present in the analyses of the smaller oligo-
saccharides. These are contaminating oligosaccharides
derived from chondroitin sulfate as indicated in subsequent
analyses (not shown) in which the samples were treated
with chondroitinase and analyzed by FACE. In each case
these bands disappeared with the appearance of disaccha-
rides characteristic of chondroitin sulfate. Thus, the original
sample of hyaluronan used for preparing the oligosac-
charides contained a small amount of chondroitin sulfate
that was converted to oligosaccharides by the testicular
hyaluronidase; and these co-purified with the respective
hyaluronan oligosaccharides.TISSUE SAMPLES
The high resolution and sensitivity of the FACE pro-
cedure makes it feasible to analyse small pieces of tissue
(in the mg range). An example of such an analysis for
hyaluronan and chondroitin sulfate in tissue from a rat
chondrosarcoma is described in detail elsewhere27. In this
case, proteinase K was used to solubilize the tissue, and
after heat inactivation of the enzyme, a portion was
fluorotagged directly and analyzed. This reveals the pres-
ence of sugars, primarily glucose, with free reducing
groups that are present in the tissue. If the amounts are
high relative to the amounts of glycosaminoglycans
expected, the latter can be precipitated with 70% ethanol
before resolubilization and further analysis.Conclusions
The methodology outlined in this chapter, once refined,
will make it feasible to quantitate each class of gly-
cosaminoglycan in small samples, and to determine many
of the details of their fine structures. For example, micro-
dissection of tissue from frozen sections and FACE analy-
sis might reveal details of regional differences, such as in
normal or pathological articular cartilage, which reflect cell
and matrix dynamics.References
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